the aid library

LIST OPTIONS

Filter

11260

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

External Link

Design and validation of a trachomatous trichiasis-only survey: strategic and technical advisory group for neglected tropical diseases, working group on monitoring and evaluation

World Health Organization WHO (2017) CC

The Fifty-first World Health Assembly adopted resolution WHA51.11 in 1998, which targets the global elimination of trachoma as a public health problem by 2020 (1). The strategy recommended to achieve that goal is encapsulated by the acronym “SAFE”, which represents: Surgery for individuals wi... more

External Link

The Expanded Special Project for Elimination of Neglected Tropical diseases — ESPEN

World Health Organization WHO (2023) C_WHO

While virtually unheard of in developed countries, NTDs are a group of medically diverse parasitic and bacterial infectious diseases common in tropical and subtropical areas. NTDs affect more than 1.5 billion people annually, causing death, blindness, disfigurement, chronic pain, cognitive impairmen... more

Download (149)

View PDF (176)

African Regional Convening to Support Parents and Caregivers

World Health Organisation (WHO) (2023) C_WHO

The African Regional Convening of the Global Initiative to Support Parents (GISP) stimulated the interest or engagement of almost 1500 individuals from 742 unique organizations in the fields of health, education, social welfare, women’s affairs, early childhood, water and sanitation, mental health... more

Préserver la Sécurité sanitaire et servir les populations vulnérables

World Health Organisation (WHO) (2023) C_WHO

Le 13ème programme général de travail (PGT) 2019-2023 de l’OMS va amorcer bientôt sa dernière année de mise en oeuvre. Cependant, le chemin vers l’objectif du « triple milliard » semble encore long, à savoir « faire en sorte qu’un milliard de personnes supplémentaires bénéficient ... more

Download (136)

View PDF (139)

Integrating psychosocial interventions and support into HIV services for adolescents and young adults

World Health Organisation (WHO) (2023) C_WHO

Adolescence, defined as the period between 10 and 19 years of age, is a developmental stage during which many psychosocial and mental health challenges emerge. There is a well-established link between mental health and HIV outcomes. Adolescents and young adults living with HIV typically have additio... more

Target product profiles for animal plasma-derived antivenoms: antivenoms for treatment of snakebite envenoming in sub-Saharan Africa

World Health Organisation (WHO) (2023) C_WHO

This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document: Broad spectrum Pan-African polyvalent antivenoms: products ... more

Download (96)

View PDF (129)

OMS Burundi_Rapport annuel 2022

World Health Organisation (WHO) (2023) C_WHO

Les activités menées au cours de l'année 2022 ont été effectuées dans le cadre de la mise en œuvre de la stratégie de coopération OMS -Burundi 2019 – 2023 et en accord avec les quatre axes stratégiques qui soustendent le Budget-Programme 2022-2023. Ce Budget-Programme (BP) est issu du 1... more

Download (176)

View PDF (164)

WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke

World Health Organisation (WHO) (2023) C_WHO

The ninth WHO report on the global tobacco epidemic tracks the progress made by countries in tobacco control since 2008 and, marks 15 years since the introduction of the MPOWER technical package which is designed to help countries implement the demand-reduction measures of the WHO Framework Conventi... more

Download (181)

View PDF (193)

WHO initiative to stop the spread of Anopheles stephensi in Africa

World Health Organisation (WHO) (2023) C_WHO

Anopheles stephensi is a mosquito species that is capable of transmitting both Plasmodium falciparum and P. vivax malaria parasites. Unlike the other main mosquito vectors of malaria, it thrives in urban and man-made environments. Originally native to parts of South Asia and the Arabian Peninsula, A... more

Download (213)

View PDF (196)

Policy brief on tuberculosis-associated disability

World Health Organization WHO (2023) C_WHO

People affected by impairments and disabilities associated with TB are even more likely to belong to marginalized segments of society and are more likely to have their human rights unprotected. The challenges faced by people affected by TB include the consequences of impairment and disability associ... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (223)

View PDF (229)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Best practices for haemoglobin measurement in population-level anaemia surveys: Technical brief (January 2024)

World Health Organization WHO; UN Children´s Fund UNICEF (2024) CC

Anaemia is a serious global public health problem that particularly affects young children, menstruating adolescent girls and women, and pregnant and postpartum women. It is a condition in which the number of red blood cells or the haemoglobin concentration within them is lower than normal, affectin... more

Framework for an Integrated Multisectoral Response to TB, HIV, STIS and Hepatitis in the WHO African Region 2021–2030

World Health Organization WHO (2024) C_WHO

Disability inclusive shelter programming enables persons with disabilities to contribute more to their communities, participate more in consultations and decision-making, and facilitate their own protection. The key concepts include: Disability inclusive shelter programming is both a process and an ... more

Global technical consultation report on proposed terminology for pathogens that transmit through the air

World Health Organization WHO (2024) C_WHO

Terminology used to describe the transmission of pathogens through the air varies across scientific disciplines, organizations and the general public. While this has been the case for decades, during the coronavirus disease (COVID-19) pandemic, the terms ‘airborne’, ‘airborne transmission’ a... more

Type 2 diabetes in adults: management

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2022) CC2

This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

Type 1 diabetes in adults

National Institute for Communicable Disease (NICE) National Institute for Communicable Disease (NICE) (2023) CC2

The document provides quality standards for managing Type 1 diabetes in adults, emphasizing areas like structured education, continuous glucose monitoring (CGM), cardiovascular risk management, and diabetic foot assessment. It aims to improve care processes, reduce complications, and enhance patient... more

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

Risk communication and community engagement readiness and response toolkit: zika virus

World Health Organisation (WHO) (2024) C_WHO

Toolkit regarding Zika Virus